Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Real time quantitative PCR.Preprint

Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767

A novel method for real time quantitative RT-PCR.Preprint

Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090

ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,617

The EGF receptor family as targets for cancer therapy

Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma

Shan, L., Qiu, T., Ling, Y., Guo, L., Zheng, B. J., Wang, B., Li, W., Li, L., & Ying, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130447 · Cited by 22

The evolving landscape of protein kinases in breast cancer: Clinical implications

Ocaña, A., Amir, E., Šeruga, B., Martín, M., & Pandiella, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.05.004 · Cited by 22

Direct regulation of caspase-3 by the transcription factor AP-2α is involved in aspirin-induced apoptosis in MDA-MB-453 breast cancer cells

YAN, F., He, Q., Hu, X., Li, W., Wei, K., Li, L., Zhong, Y., Ding, X., Xiang, S., & Zhang, J. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1257 · Cited by 22

Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis

Lahlou, H., Müller, T. H., Sanguin‐Gendreau, V., Birchmeier, C., & Muller, W. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3513 · Cited by 22

Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab

Zhang, Y., Wu, S., Zhuang, X., Weng, G., Fan, J., Yang, X., Xu, Y., Pan, L., Hou, T., Zhou, Z. M., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s232912 · Cited by 23

Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms

Ashrafizadeh, M., Mohammadinejad, R., Samarghandian, S., Yaribeygi, H., Johnston, T. P., & Sahebkar, A. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200228110704 · Cited by 22

Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel

Cortés, J., Swain, S. M., Kudaba, I., Hauschild, M., Patel, T. N., Grincuka, E., Masuda, N., McNally, V. A., Ross, G. A., Brewster, M., et al. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000016 · Cited by 21

Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma

Hosni, S., Kilian, V., Klümper, N., Gabbia, D., Sieckmann, K., Corvino, D., Winkler, A., Saponaro, M., Wörsdörfer, K., Schmidt, D. H., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1398 · Cited by 21

Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment

Belimezi, M., Papanastassiou, D., Merkouri, E., Baxevanis, C. N., & Mamalaki, A. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0100-z · Cited by 21

Pertuzumab in the Treatment of HER2+Breast Cancer

Jhaveri, K. L., & Esteva, F. J. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0059 · Cited by 21

Role of pertuzumab in the treatment of HER2-positive breast cancer

Hubalek, M., Brantner, C., & Marth, C. (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s23560 · Cited by 21

Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli

Akbari, V., Hamid, M., Jafarian‐Dehkordi, A., Abedi, D., & Chou, C.-H. P. (2015) · Protein Expression and Purification · doi:10.1016/j.pep.2015.07.005 · Cited by 21

Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects

Martin, L. P., & Schilder, R. J. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.0079 · Cited by 21

Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.

O'Sullivan, C. C., & Connolly, R. M. (2014) · PubMed · Cited by 20

Precision medicine and personalized breast cancer: combination pertuzumab therapy

Dizon, D. S., Reynolds, K., Sarangi, S., & Bardia, A. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s37100 · Cited by 20

Targeting endothelin A receptor enhances anti‐proliferative and anti‐invasive effects of the HER2 antibody trastuzumab in HER2‐overexpressing breast cancer cells

Fischgräbe, J., Götte, M., Michels, K., Kiesel, L., & Wülfing, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.25076 · Cited by 20

Docetaxel combined with targeted therapies in metastatic breast cancer

Cortés, J., & Roche, H. H. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.08.001 · Cited by 20

Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress?

Raben, D., Bianco, C., Milas, L., & Ang, K. K. (2004) · Seminars in Radiation Oncology · doi:10.1053/j.semradonc.2003.12.009 · Cited by 20

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer

Sun, J., Li, X., Chen, P., & Gao, Y. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s368138 · Cited by 19

Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development

Gautam, N., Ramamoorthi, G., Champion, N., Han, H. S., & Czerniecki, B. J. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101239 · Cited by 19

A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy

Kaumaya, P. T. P. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1026495 · Cited by 19

Autorisation de mise sur le marché du trastuzumab emtansine (Kadcyla®) dans les cancers du sein métastatiques HER2-positifs

Guérin, M., Sabatier, R., & Gonçalvès, A. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.02.007 · Cited by 20

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers

Osada, T., Hartman, Z. C., Wei, J.-P., Lei, G., Hobeika, A. C., Gwin, W. R., Diniz, M. A., Spector, N. L., Clay, T. M., Chen, W., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1023-x · Cited by 18

Effects of variable domain orientation on anti‐HER2 single‐chain variable fragment antibody expressed in the Escherichia coli cytoplasm

Koçer, İ., Cox, E. C., DeLisa, M. P., & Çelik, E. (2020) · Biotechnology Progress · doi:10.1002/btpr.3102 · Cited by 18

Current status of antibody therapy for breast cancer

Toi, M., Takada, M., Bando, H., Toyama, K., Yamashiro, H., Horiguchi, S., & Saji, S. (2004) · Breast Cancer · doi:10.1007/bf02967994 · Cited by 19

Structure–activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines

Banappagari, S., Ronald, S., & Satyanarayanajois, S. D. (2011) · MedChemComm · doi:10.1039/c1md00126d · Cited by 19

Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives

Dormann, C. (2020) · Breast Care · doi:10.1159/000512328 · Cited by 20

Cardiac Toxicity From Adjuvant Targeting Treatment for Breast Cancer Post-Surgery

Fu, Z., Lin, Z., Yang, M. S., & Li, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.706861 · Cited by 18

Detailed curriculum vitae of HER2-targeted therapy

Zhang, X., Gao, Y., Zhang, X.-Y., Guo, N.-J., Hou, W., Wang, S.-W., Zheng, Y., Wang, N., Liu, H., & Wang, B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108417 · Cited by 19

Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic

Fabi, A., Mottolese, M., & Segatto, O. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1169-7 · Cited by 18

Flow Cytometric FRET Analysis of erbB Receptor Interaction on a Cell‐by‐Cell Basis

Diermeier‐Daucher, S., Hasmann, M., & Brockhoff, G. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1430.003 · Cited by 18

HER3 mRNA as a predictive biomarker in anticancer therapy

Amler, L. C. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.512003 · Cited by 18

Targeting HER2 by Combination Therapies

Ruiz-Sáenz, A., & Moasser, M. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.1899 · Cited by 18

Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro

Wang, H., Wang, Y., Xiao, Z., Li, W., Dimitrov, D. S., & Chen, W. (2019) · Antibodies · doi:10.3390/antib8010025 · Cited by 18

Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer

O'Sullivan, C. C., & Swain, S. M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.783007 · Cited by 18

The EGF Receptor Family as Therapeutic Targets in Breast Cancer

Lemmon, M. A. (2003) · Breast Disease · doi:10.3233/bd-2003-18105 · Cited by 18

Potential use of humanized antibodies in the treatment of breast cancer

Schaefer, N. G., Pestalozzi, B. C., Knuth, A. K., & Renner, C. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1065 · Cited by 18

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

MacNeil, I. A., Burns, D. J., Rich, B. E., Soltani, S. M., Kharbush, S., Osterhaus, N. G., Sullivan, B. F., Hawkins, D. M., Pietruska, J. R., & Laing, L. G. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03144-7 · Cited by 17

NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells

Miano, C., Morselli, A., Pontis, F., Bongiovanni, C., Sacchi, F., Pra, S. D., Romaniello, D., Tassinari, R., Sgarzi, M., Pantano, E., et al. (2022) · Cancers · doi:10.3390/cancers14071603 · Cited by 17

Pertuzumab for the Treatment of Breast Cancer

Lynce, F. C., & Swain, S. M. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.922570 · Cited by 17

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer

Chung, C., & Lam, M. S. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120735 · Cited by 17

Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells

Huang, Y., Burns, D. J., Rich, B. E., MacNeil, I. A., Dandapat, A., Soltani, S. M., Myhre, S., Sullivan, B. F., Lange, C. A., Furcht, L. T., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3181-0 · Cited by 18

Single Technology Appraisal

Culyer, A. J. (2014) · Cited by 17

Antibody-Based Imaging of HER-2: Moving into the Clinic

Wang, R. E., Zhang, Y., Tian, L., Cai, W., & Cai, J. (2013) · Current Molecular Medicine · doi:10.2174/1566524013666131111120951 · Cited by 17

Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy

Hirsch, D. S., & Wu, W. J. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.2.147 · Cited by 17

Treating the HER2 Pathway in Early and Advanced Breast Cancer

Pegram, M. D. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.05.007 · Cited by 16

Implications of EGFR PharmDx™ Kit for cetuximab eligibility

Ensinger, C., & Sterlacci, W. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.2.141 · Cited by 16

The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.

Morishita, A., Gong, J., Nomura, T., Yoshida, H., Izuishi, K., Suzuki, Y., Kushida, Y., Haba, R., D'Armiento, J., & Masaki, T. (2010) · International Journal of Oncology · doi:10.3892/ijo_00000733 · Cited by 16

Pertuzumab in Breast Cancer: A Systematic Review

Zagouri, F., Sergentanis, T. Ν., Chrysikos, D., Zografos, C. G., Filipits, M., Bartsch, R., Dimopoulos, M. A., & Ψαλτοπούλου, Θ. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.05.002 · Cited by 16

Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer

Mukohara, T. (2011) · Chemotherapy Research and Practice · doi:10.1155/2011/730360 · Cited by 17

Genomic and epigenomic alterations in prostate cancer

Aschelter, A. M., Giacinti, S., Caporello, P., & Marchetti, P. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00128 · Cited by 16

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

Campbell, M. R., Ruiz-Sáenz, A., Zhang, Y., Peterson, E., Steri, V., Oeffinger, J., Sampang, M., Jura, N., & Moasser, M. M. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110285 · Cited by 16

Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer

Smith, M., Reardon, J., & Olson, E. M. (2012) · Drugs of today · doi:10.1358/dot.2012.48.11.1885879 · Cited by 16

ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo

Foreman, P. K., Gore, M., Kobel, P. A., Xu, L., Yee, H., Hannum, C. H., Ho, H., Wang, S. M., Tran, H. V., Horowitz, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0068 · Cited by 16

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors

Meng, Y., Zheng, L., Yang, Y., Wang, H.-J., Dong, J., Wang, C., Zhang, Y., Yu, X., Wang, L., Xia, T., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.25 · Cited by 16

Targeted therapies in solid tumors: Monoclonal antibodies and small molecules

Weiner, L. M., & Borghaei, H. (2006) · Human Antibodies · doi:10.3233/hab-2006-15305 · Cited by 16

The ErbB2 inhibitor Herceptin (Trastuzumab) promotes axonal outgrowth four weeks after acute nerve transection and repair

Placheta, E., Hendry, J. M., Wood, M. D., Lafontaine, C. W., Liu, E. H., Alvarez‐Veronesi, M. C., Frey, M., Gordon, T., & Borschel, G. H. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.09.006 · Cited by 16

HER-dimerization inhibitors: evaluating pertuzumab in women's cancers

Kristjánsdóttir, K., & Dizon, D. S. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903514090 · Cited by 16

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy

Gutsch, D., Jenke, R., Büch, T., & Aigner, A. M. (2021) · Cells · doi:10.3390/cells10020272 · Cited by 15

A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells

Maadi, H., & Wang, Z. (2022) · Cells · doi:10.3390/cells11244093 · Cited by 16

Pertuzumab in gastrointestinal cancer

Oh, D., & Bang, Y. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1126578 · Cited by 15

Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy

Rocca, A., Andreis, D., Fedeli, A., Maltoni, R., Sarti, S., Cecconetto, L., Pietri, E., Schirone, A., Bravaccini, S., Serra, P., et al. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1078311 · Cited by 16

Analysis of the interplay between methylation and expression reveals its potential role in cancer aetiology

Özer, B., & Sezerman, O. U. (2016) · Functional & Integrative Genomics · doi:10.1007/s10142-016-0533-9 · Cited by 15

Emerging role of EGFR-targeted therapies and radiation in head and neck cancer.

Song, J. I., Chen, C., & Raben, D. (2004) · PubMed · Cited by 15

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Iyengar, N. M., Smyth, L. M., Lake, D. E., Gucalp, A., Singh, J. C., Traina, T. A., DeFusco, P. A., Fornier, M. N., Goldfarb, S. B., Jhaveri, K. L., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16211 · Cited by 14

Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma

Gameiro, A., Urbano, A. C., & Ferreira, F. (2021) · Veterinary Sciences · doi:10.3390/vetsci8080164 · Cited by 19

Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling

Diermeier‐Daucher, S., Ortmann, O., Buchholz, S., & Brockhoff, G. (2012) · mAbs · doi:10.4161/mabs.21003 · Cited by 14

Oncogenicity of LHX4 in colorectal cancer through Wnt/β-catenin/TCF4 cascade

Cha, N., Liu, W., Yang, N. Y., Xie, S., Gao, Y., Chen, X., Wang, X., & Ren, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2210-8 · Cited by 14

Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis

Franco‐Gonzalez, J. F., Cruz, V. L., Ramos, J., & Martínez‐Salazar, J. (2012) · Journal of Molecular Modeling · doi:10.1007/s00894-012-1661-3 · Cited by 14

Re-epithelialization from human skin explant cultures is promoted by ligand-activated HER3 receptor

Forsberg, S., & Rollman, O. (2010) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2010.03.017 · Cited by 14

LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer

Takahashi, S., Kobayashi, T., Tomomatsu, J., Ito, Y., Oda, H., Kajitani, T., Kakizume, T., Tajima, T., Takeuchi, H., Maacke, H., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3214-4 · Cited by 14

bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies

Patke, S., Li, J., Wang, P., Slaga, D., Johnston, J., Bhakta, S., Panowski, S. H., Sun, L. L., Junttila, T. T., Scheer, J. M., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1281504 · Cited by 14

Monoclonal Antibody Therapy for Prostate Cancer

Jakobovits, A. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_11 · Cited by 14

Prostate cancer cell lines lack amplification: Overexpression of HER2

Ullén, A., Lennartsson, L., Harmenberg, U., Lennernäs, B., Majumder, K., Holmberg, A., Nilsson, S. F., & Elmberger, G. (2005) · Acta Oncologica · doi:10.1080/02841860510029888 · Cited by 14

HER-2/Neu signaling and therapeutic approaches in breast cancer

Zhou, B. P., Li, Y., & Hung, M. (2002) · Breast Disease · doi:10.3233/bd-2002-15103 · Cited by 14

The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation

Centa, A., Barrueco, R. R., Montero, J. C., & Pandiella, A. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12310 · Cited by 13

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)

Yamashita, T., Kawaguchi, H., Masuda, N., Kitada, M., Narui, K., Hattori, M., Yoshinami, T., Matsunami, N., Yanagihara, K., Kawasoe, T., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00991-6 · Cited by 13

LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy

Zhang, Y., Yang, J., Wang, J., Guo, H., & Jing, N. (2014) · Medical Oncology · doi:10.1007/s12032-014-0099-0 · Cited by 13

The function of human epidermal growth factor receptor-3 and its role in tumors (Review).

Li, Q., Yuan, Z., & Cao, B. (2013) · Oncology Report · doi:10.3892/or.2013.2754 · Cited by 15

Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer

Dawood, S. S., & Sirohi, B. (2015) · Future Oncology · doi:10.2217/fon.15.7 · Cited by 13

APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis

Hong, S.-H., Lee, W., Kim, Y. D., Kim, H. J., Jeon, Y.-J., Lim, B., Cho, D., Heo, W. D., Yang, D.-H., Kim, C. Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7802 · Cited by 13

Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect

Wang, M., Hu, Y., Yu, T., Ma, X., Wei, X., & Wei, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.014 · Cited by 14

Pertuzumab for the treatment of breast cancer

Robert, M., Frenel, J., Bourbouloux, E., Rigaud, D. B., Patsouris, A., Augereau, P., Gourmelon, C., & Campone, M. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1596805 · Cited by 13

Autorisation de mise sur le marché du pertuzumab (Perjeta®) dans les cancers du sein métastatiques HER2 positifs

Sabatier, R., & Gonçalvès, A. (2014) · Bulletin du Cancer · doi:10.1684/bdc.2014.1940 · Cited by 13

Essential function for ErbB3 in breast cancer proliferation

Pérez‐Nadales, E., & Lloyd, A. C. (2004) · Breast Cancer Research · doi:10.1186/bcr792 · Cited by 13

Trans-activating mutations of the pseudokinase ERBB3

Koivu, M. K. A., Chakroborty, D., Airenne, T. T., Johnson, M. S., Kurppa, K. J., & Elenius, K. (2024) · Oncogene · doi:10.1038/s41388-024-03070-9 · Cited by 12

Pertuzumab Protects the Achilles' Heel of Trastuzumab—Emtansine

Gwin, W. R., & Spector, N. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2626 · Cited by 12

Diarrhea With HER2‐Targeted Agents in Cancer Patients: A Systematic Review and Meta‐Analysis

Li, J. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1382 · Cited by 12

Homo- and Heteroassociations Drive Activation of ErbB3

Váradi, T., Schneider, M. C., Sevcsik, E., Kiesenhofer, D., Baumgart, F., Batta, G., Kovács, T., Platzer, R., Huppa, J. B., Szöllõsi, J., et al. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.10.001 · Cited by 12

The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers

Lemieux, J., Clemons, M. J., Provencher, L., Dent, S., Latreille, J., Mackey, J., Pritchard, K. I., Rayson, D., Verma, S., Verma, S., et al. (2009) · Current Oncology · doi:10.3747/co.v16i5.510 · Cited by 12

Improving the efficacy of trastuzumab in breast cancer

Suzuki, E., & Toi, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00455.x · Cited by 12

Whither HER2-Related Therapeutics?

De, P. K., & Leyland-Jones, B. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8624 · Cited by 12

Construction and Characterization of a New Chimeric Antibody Against HER2

Amiri, M. M., Jeddi‐Tehrani, M., Kazemi, T., Bahadori, M., Maddah, M., Hojjat‐Farsangi, M., Khoshnoodi, J., Rabbani, H., & Shokri, F. (2013) · Immunotherapy · doi:10.2217/imt.13.67 · Cited by 11

Targeting HER2 in breast cancer: overview of long-term experience

Higa (2009) · International Journal of Women s Health · doi:10.2147/ijwh.s5647 · Cited by 11

Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H 2 Mab-181) Using Enzyme-Linked Immunosorbent Assay

Asano, T., Takei, J., Suzuki, H., Kaneko, M. K., & Kato, Y. (2021) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2021.0029 · Cited by 11

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer

Álvarez, R. H., & Hortobágyi, G. N. (2013) · Breast Cancer · doi:10.1007/s12282-013-0446-6 · Cited by 11

Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis

Cepero, V., Sierra, J. R., & Giordano, S. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791033905 · Cited by 11

Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer

Sonke, G. S., Mandjes, I. A. M., Holtkamp, M., Schot, M. E., van Werkhoven, E. D., Wesseling, J., Peeters, M.-J. T. F. D. V., Rodenhuis, S., & Linn, S. C. (2013) · The Breast Journal · doi:10.1111/tbj.12124 · Cited by 11

HER2 Signaling in Breast Cancer

Shin, I. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_3 · Cited by 11

Biological considerations and clinical applications of new HER2-targeted agents

Higa, G. M., Singh, V., & Abraham, J. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.129 · Cited by 11

Stop signals

Greenwood, E. (2002) · Nature reviews. Cancer · doi:10.1038/nrc892

Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects

Jackson, J. G., Clair, P. S., Sliwkowski, M. X., & Brattain, M. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3106 · Cited by 104

Changes in heregulin β1 (HRGβ1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line

Yoo, J.-Y., & Hamburger, A. W. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00004-5 · Cited by 7

Erb-2/HER2 Oncogene in Breast Cancer: Does Bivalency of Growth Factors Drive Tumorigenicity Through Receptor Heterodimerization

Yarden, Y. (1999) · doi:10.21236/ada382955

Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells

Grunt, T. W., Saceda, M., Martin, M. B., Lupu, R., Dittrich, E., Krupitza, G., Harant, H., Huber, H. P., & Dittrich, C. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630417 · Cited by 70